Literature DB >> 23868984

IGFBP-3 and TNF-α regulate retinal endothelial cell apoptosis.

Qiuhua Zhang1, Youde Jiang, Matthew J Miller, Bonnie Peng, Li Liu, Carl Soderland, Jie Tang, Timothy S Kern, John Pintar, Jena J Steinle.   

Abstract

PURPOSE: We hypothesized that loss of insulin-like growth factor binding protein 3 (IGFBP-3) signaling would produce neuronal changes in the retina similar to early diabetes.
METHODS: To understand better the role of IGFBP-3 in the retina, IGFBP-3 knockout (KO) mice were evaluated for neuronal, vascular, and functional changes compared to wild-type littermates. We also cultured retinal endothelial cells (REC) in normoglycemia or hyperglycemia to determine the interaction between IGFBP-3 and TNF-α, as data indicate that both proteins are regulated by β-adrenergic receptors and respond antagonistically. We also treated some cells with Compound 49b, a novel β-adrenergic receptor agonist we have reported previously to regulate IGFBP-3 and TNF-α.
RESULTS: Electroretinogram analyses showed decreased B-wave and oscillatory potential amplitudes in the IGFBP-3 KO mice, corresponding to increased apoptosis. Retinal thickness and cell numbers in the ganglion cell layer were reduced in the IGFBP-3 KO mice. As expected, loss of IGFBP-3 was associated with increased TNF-α levels. When TNF-α and IGFBP-3 were applied to REC, they worked antagonistically, with IGFBP-3 inhibiting apoptosis and TNF-α promoting apoptosis. Due to their antagonistic nature, results suggest that apoptosis of REC may depend upon which protein (IGFBP-3 versus TNF-α) is active.
CONCLUSIONS: Taken together, loss of IGFBP-3 signaling results in a phenotype similar to neuronal changes observed in diabetic retinopathy in the early phases, including increased TNF-α levels.

Entities:  

Keywords:  IGFBP-3; TNF-α; apoptosis

Mesh:

Substances:

Year:  2013        PMID: 23868984      PMCID: PMC3741024          DOI: 10.1167/iovs.13-12497

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  30 in total

1.  Free insulin-like growth factor binding protein-3 (IGFBP-3) reduces retinal vascular permeability in association with a reduction of acid sphingomyelinase (ASMase).

Authors:  Jennifer L Kielczewski; Sergio Li Calzi; Lynn C Shaw; Jun Cai; Xiaoping Qi; Qing Ruan; Lin Wu; Li Liu; Ping Hu; Tailoi Chan-Ling; Robert N Mames; Sue Firth; Robert C Baxter; Patric Turowski; Julia V Busik; Michael E Boulton; Maria B Grant
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-10-21       Impact factor: 4.799

2.  Tumor necrosis factor-alpha regulates insulin-like growth factor-1 and insulin-like growth factor binding protein-3 expression in vascular smooth muscle.

Authors:  A Anwar; A A Zahid; K J Scheidegger; M Brink; P Delafontaine
Journal:  Circulation       Date:  2002-03-12       Impact factor: 29.690

3.  Regulation of retinal endothelial cell apoptosis through activation of the IGFBP-3 receptor.

Authors:  Qiuhua Zhang; Carl Soderland; Jena J Steinle
Journal:  Apoptosis       Date:  2013-03       Impact factor: 4.677

4.  Compound 49b prevents diabetes-induced apoptosis through increased IGFBP-3 levels.

Authors:  Qiuhua Zhang; Kimberly Guy; Jayaprakash Pagadala; Youde Jiang; Robert J Walker; Luhong Liu; Carl Soderland; Timothy S Kern; Robert Ferry; Hui He; C Ryan Yates; Duane D Miller; Jena J Steinle
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-05-17       Impact factor: 4.799

5.  Novel protective properties of IGFBP-3 result in enhanced pericyte ensheathment, reduced microglial activation, increased microglial apoptosis, and neuronal protection after ischemic retinal injury.

Authors:  Jennifer L Kielczewski; Ping Hu; Lynn C Shaw; Sergio Li Calzi; Robert N Mames; Tom A Gardiner; Evan McFarland; Tailoi Chan-Ling; Maria B Grant
Journal:  Am J Pathol       Date:  2011-04       Impact factor: 4.307

6.  Insulin-like growth factor binding protein-3 mediates tumor necrosis factor-alpha-induced apoptosis: role of Bcl-2 phosphorylation.

Authors:  Roopmathy Rajah; Kuk-Wha Lee; Pinchas Cohen
Journal:  Cell Growth Differ       Date:  2002-04

7.  Comparison of three strains of diabetic rats with respect to the rate at which retinopathy and tactile allodynia develop.

Authors:  T S Kern; C M Miller; J Tang; Y Du; S L Ball; L Berti-Matera
Journal:  Mol Vis       Date:  2010-08-15       Impact factor: 2.367

8.  DNA-PK phosphorylation of IGFBP-3 is required to prevent apoptosis in retinal endothelial cells cultured in high glucose.

Authors:  Qiuhua Zhang; Jena J Steinle
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-04-30       Impact factor: 4.799

9.  Application of isoproterenol inhibits diabetic-like changes in the rat retina.

Authors:  Youde Jiang; Robert J Walker; Timothy S Kern; Jena J Steinle
Journal:  Exp Eye Res       Date:  2010-05-21       Impact factor: 3.467

10.  Increased tumor necrosis factor-α, cleaved caspase 3 levels and insulin receptor substrate-1 phosphorylation in the β₁-adrenergic receptor knockout mouse.

Authors:  Surekha Rani Panjala; Youde Jiang; Timothy S Kern; Steven A Thomas; Jena J Steinle
Journal:  Mol Vis       Date:  2011-07-06       Impact factor: 2.367

View more
  27 in total

1.  Mesenchymal Stromal Cells Mitigate Experimental Colitis via Insulin-like Growth Factor Binding Protein 7-mediated Immunosuppression.

Authors:  Yan Liao; Junxia Lei; Muyun Liu; Wanwen Lin; Dongxi Hong; Ying Tuo; Mei Hua Jiang; Huimin Xia; Maosheng Wang; Weijun Huang; Andy Peng Xiang
Journal:  Mol Ther       Date:  2016-07-09       Impact factor: 11.454

2.  Pioglitazone restores IGFBP-3 levels through DNA PK in retinal endothelial cells cultured in hyperglycemic conditions.

Authors:  Shalini Thakran; Qiuhua Zhang; Vanessa Morales-Tirado; Jena J Steinle
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-12-18       Impact factor: 4.799

3.  PKA regulates HMGB1 through activation of IGFBP-3 and SIRT1 in human retinal endothelial cells cultured in high glucose.

Authors:  Li Liu; Paragi Patel; Jena J Steinle
Journal:  Inflamm Res       Date:  2018-10-17       Impact factor: 4.575

4.  Beta-adrenergic receptor agonist decreases VEGF levels through altered eNOS and PKC signaling in diabetic retina.

Authors:  Youde Jiang; Qiuhua Zhang; Jena J Steinle
Journal:  Growth Factors       Date:  2015-06-26       Impact factor: 2.511

5.  TLR4 regulates insulin-resistant proteins to increase apoptosis in the mouse retina.

Authors:  Li Liu; Youde Jiang; Elizabeth Curtiss; Ken-Ichiro Fukuchi; Jena J Steinle
Journal:  Inflamm Res       Date:  2017-07-05       Impact factor: 4.575

6.  Adipose-derived stem cells from diabetic mice show impaired vascular stabilization in a murine model of diabetic retinopathy.

Authors:  Stephen M Cronk; Molly R Kelly-Goss; H Clifton Ray; Thomas A Mendel; Kyle L Hoehn; Anthony C Bruce; Bijan K Dey; Alexander M Guendel; Daniel N Tavakol; Ira M Herman; Shayn M Peirce; Paul A Yates
Journal:  Stem Cells Transl Med       Date:  2015-03-13       Impact factor: 6.940

7.  A sensitive and fast LC-MS/MS method for determination of β-receptor agonist JP-49b: application to a pharmacokinetic study in rats.

Authors:  Hui He; Kimberly Williams-Guy; Jayaprakash Pagadala; Chaela Sickbert Presley; Duane D Miller; Jena J Steinle; Charles R Yates
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2014-02-08       Impact factor: 3.205

8.  Insulin-like growth factor-1 binding protein 3 (IGFBP-3) promotes recovery from trauma-induced expression of inflammatory and apoptotic factors in retina.

Authors:  Youde Jiang; Jayaprakash Pagadala; Duane D Miller; Jena J Steinle
Journal:  Cytokine       Date:  2014-07-28       Impact factor: 3.861

9.  IGFBP-3 inhibits TNF-α production and TNFR-2 signaling to protect against retinal endothelial cell apoptosis.

Authors:  Qiuhua Zhang; Jena J Steinle
Journal:  Microvasc Res       Date:  2014-07-30       Impact factor: 3.514

10.  Nerve growth factor in diabetic retinopathy: beyond neurons.

Authors:  Barbara A Mysona; Ahmed Y Shanab; Sally L Elshaer; Azza B El-Remessy
Journal:  Expert Rev Ophthalmol       Date:  2014-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.